Fig. 1
Overall survival (a) and cancer specific survival (b) in patients treated with degarelix and patients in whom degarelix was switched to gonadotropin releasing hormone agonist
Fig. 1 | Basic and Clinical Andrology
Overall survival (a) and cancer specific survival (b) in patients treated with degarelix and patients in whom degarelix was switched to gonadotropin releasing hormone agonist
Basic and Clinical Andrology